Amin A. Nomeir - Concepedia

Author

Amin A. Nomeir

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

A A Nomeir, A NOMEIR, A Nomeir, A. A. Nomeir, A. Nomeir, A.A. Nomeir, AMIN A. NOMEIR, Ahmed Salama Soliman Nomeir, Amin A Nomeir, Amin A. Nomeir

165

Publications

4.6K

Citations

H-Index

108

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Duke Medical Center PharmacoGenetics (China)Duke University LabCorp (United States)

About

Amin A. Nomeir is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	65	3.1K
2	Natural Sciences	17	22	808
3	Engineering	6	6	163
4	Health Sciences	4	4	99
5	Allergy	2	2	97

Amin A. Nomeir

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor David Parry, Timothy J. Guzi, Nicole R. Davis, Molecular Cancer Therapeutics PharmacotherapyCancer BiologyTumor BiologyCdk9 ActivityReceptor Tyrosine Kinase	2010	553
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Ming Liu, Matthew Bryant, Jianping Chen, PubMed Sch 66336Chemoprevention StrategyFarnesyl Protein TransferaseOncogenic AgentMedicine	1998	309
The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America Scott Grimm, Heidi J. Einolf, Steven D. Hall, Drug Metabolism and Disposition	2009	304
Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity Craig A. Coburn, Peter T. Meinke, Wei Chang, ChemMedChem Hcv Ns5a InhibitorBroad Genotype ActivityVitro Potency ProfilesImmunologyPharmacotherapy	2013	196
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases Kamil Paruch, Michael P. Dwyer, Carmen Álvarez, ACS Medicinal Chemistry Letters Drug TargetPathologyChemical BiologyPharmaceutical ChemistryTumor Biology	2010	174
Cassette‐accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery Walter A. Korfmacher, Kathleen Cox, Kwokei Ng, Rapid Communications in Mass Spectrometry	2001	151
Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2 Gopal Krishna, Kwang-jong Chen, Chin-chung Lin, International Journal of Pharmaceutics Pharmaceutical ScienceBiochemistryMedicineLipophilic CompoundsPharmacology	2001	142
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]- pyridin-11(<i>R</i>)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent F. George Njoroge, Arthur G. Taveras, Joseph Kelly, Journal of Medicinal Chemistry Bioorganic ChemistryPharmacotherapyPharmaceutical ChemistryTricyclic Ring SystemBromine Atom	1998	97
Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive Veijo Saano, Paul Glue, Christopher Banfield, Clinical Pharmacology & Therapeutics	1995	93
Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice Eva‐Pia Reich, Long Cui, Lily Yang, European Journal of Immunology T-regulatory CellImmunologyImmune RegulationCd4 T Cell ResponsesImmunotherapy	2005	87

Page 1